Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 155Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Large B-Cell, Diffuse 26Lymphoma 25Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 22Recurrence 21Neoplasms, Plasma Cell 19Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 8Smoldering Multiple Myeloma 8Hodgkin Disease 8Prostatic Neoplasms 7Lymphoma, B-Cell 6Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Hematologic Diseases 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Leukemia, Myelomonocytic, Chronic 4Immunoblastic Lymphadenopathy 4Anemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Lymphoma, T-Cell, Cutaneous 3

Interventions

tafasitamab 1fludarabine 1acalabrutinib 1Valganciclovir 1N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 1Lenalidomide 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pyloric Stenosis, Hypertrophic × Lenalidomide × Clear all
NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Xencor, Inc.

Phase 2 Terminated
3 enrolled 6 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡